Doppler ultrasound surveillance of recently formed haemodialysis arteriovenous fistula: the SONAR observational cohort study.

ARTERIOVENOUS FISTULA CHRONIC: HAEMODIALYSIS DOPPLER FEASIBILITY STUDIES KIDNEY FAILURE OBSERVATIONAL COHORT STUDY RENAL DIALYSIS ULTRASONOGRAPHY VASCULAR ACCESS SURGERY

Journal

Health technology assessment (Winchester, England)
ISSN: 2046-4924
Titre abrégé: Health Technol Assess
Pays: England
ID NLM: 9706284

Informations de publication

Date de publication:
May 2024
Historique:
medline: 20 5 2024
pubmed: 20 5 2024
entrez: 20 5 2024
Statut: ppublish

Résumé

Arteriovenous fistulas are considered the best option for haemodialysis provision, but as many as 30% fail to mature or suffer early failure. To assess the feasibility of performing a randomised controlled trial that examines whether, by informing early and effective salvage intervention of fistulas that would otherwise fail, Doppler ultrasound surveillance of developing arteriovenous fistulas improves longer-term arteriovenous fistula patency. A prospective multicentre observational cohort study (the 'SONAR' study). Seventeen haemodialysis centres in the UK. Consenting adults with end-stage renal disease who were scheduled to have an arteriovenous fistula created. Participants underwent Doppler ultrasound surveillance of their arteriovenous fistulas at 2, 4, 6 and 10 weeks after creation, with clinical teams blinded to the ultrasound surveillance findings. Fistula maturation at week 10 defined according to ultrasound surveillance parameters of representative venous diameter and blood flow (wrist arteriovenous fistulas: ≥ 4 mm and > 400 ml/minute; elbow arteriovenous fistulas: ≥ 5 mm and > 500 ml/minute). Mixed multivariable logistic regression modelling of the early ultrasound scan data was used to predict arteriovenous fistula non-maturation by 10 weeks and fistula failure at 6 months. A total of 333 arteriovenous fistulas were created during the study window (47.7% wrist, 52.3% elbow). By 2 weeks, 37 (11.1%) arteriovenous fistulas had failed (thrombosed), but by 10 weeks, 219 of 333 (65.8%) of created arteriovenous fistulas had reached maturity (60.4% wrist, 67.2% elbow). Persistently lower flow rates and venous diameters were observed in those fistulas that did not mature. Models for arteriovenous fistulas' non-maturation could be optimally constructed using the week 4 scan data, with fistula venous diameter and flow rate the most significant variables in explaining wrist fistula maturity failure (positive predictive value 60.6%, 95% confidence interval 43.9% to 77.3%), whereas resistance index and flow rate were most significant for elbow arteriovenous fistulas (positive predictive value 66.7%, 95% confidence interval 48.9% to 84.4%). In contrast to non-maturation, both models predicted fistula maturation much more reliably [negative predictive values of 95.4% (95% confidence interval 91.0% to 99.8%) and 95.6% (95% confidence interval 91.8% to 99.4%) for wrist and elbow, respectively]. Additional follow-up and modelling on a subset ( Although early ultrasound can predict fistula maturation and longer-term patency very effectively, it was only moderately good at identifying those fistulas likely to remain immature or to fail within 6 months. Allied to the better- than-expected fistula patency rates achieved (that are further improved by successful salvage), we estimate that a randomised controlled trial comparing early ultrasound-guided intervention against standard care would require at least 1300 fistulas and would achieve only minimal patient benefit. This trial is registered as ISRCTN36033877 and ISRCTN17399438. This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR135572) and is published in full in For people with advanced kidney disease, haemodialysis is best provided by an ‘arteriovenous fistula’, which is created surgically by joining a vein onto an artery at the wrist or elbow. However, these take about 2 months to develop fully (‘mature’), and as many as 3 out of 10 fail to do so. We asked whether we could use early ultrasound scanning of the fistula to identify those that are unlikely to mature. This would allow us to decide whether it would be practical to run a large, randomised trial to find out if using early ultrasound allows us to ‘rescue’ fistulas that would otherwise fail. We invited adults to undergo serial ultrasound scanning of their fistula in the first few weeks after it was created. We then analysed whether we could use the data from the early scans to identify those fistulas that were not going to mature by week 10. Of the 333 fistulas that were created, about two-thirds reached maturity by week 10. We found that an ultrasound scan 4 weeks after fistula creation could reliably identify those fistulas that were going to mature. However, of those fistulas predicted to fail, about one-third did eventually mature without further intervention, and even without knowing what the early scans showed, another third were successfully rescued by surgery or X-ray-guided treatment at a later stage. Performing an early ultrasound scan on a fistula can provide reassurance that it will mature and deliver trouble-free dialysis. However, because scans are poor at identifying fistulas that are unlikely to mature, we would not recommend their use to justify early surgery or X-ray-guided treatment in the expectation that this will improve outcomes.

Sections du résumé

Background UNASSIGNED
Arteriovenous fistulas are considered the best option for haemodialysis provision, but as many as 30% fail to mature or suffer early failure.
Objective UNASSIGNED
To assess the feasibility of performing a randomised controlled trial that examines whether, by informing early and effective salvage intervention of fistulas that would otherwise fail, Doppler ultrasound surveillance of developing arteriovenous fistulas improves longer-term arteriovenous fistula patency.
Design UNASSIGNED
A prospective multicentre observational cohort study (the 'SONAR' study).
Setting UNASSIGNED
Seventeen haemodialysis centres in the UK.
Participants UNASSIGNED
Consenting adults with end-stage renal disease who were scheduled to have an arteriovenous fistula created.
Intervention UNASSIGNED
Participants underwent Doppler ultrasound surveillance of their arteriovenous fistulas at 2, 4, 6 and 10 weeks after creation, with clinical teams blinded to the ultrasound surveillance findings.
Main outcome measures UNASSIGNED
Fistula maturation at week 10 defined according to ultrasound surveillance parameters of representative venous diameter and blood flow (wrist arteriovenous fistulas: ≥ 4 mm and > 400 ml/minute; elbow arteriovenous fistulas: ≥ 5 mm and > 500 ml/minute). Mixed multivariable logistic regression modelling of the early ultrasound scan data was used to predict arteriovenous fistula non-maturation by 10 weeks and fistula failure at 6 months.
Results UNASSIGNED
A total of 333 arteriovenous fistulas were created during the study window (47.7% wrist, 52.3% elbow). By 2 weeks, 37 (11.1%) arteriovenous fistulas had failed (thrombosed), but by 10 weeks, 219 of 333 (65.8%) of created arteriovenous fistulas had reached maturity (60.4% wrist, 67.2% elbow). Persistently lower flow rates and venous diameters were observed in those fistulas that did not mature. Models for arteriovenous fistulas' non-maturation could be optimally constructed using the week 4 scan data, with fistula venous diameter and flow rate the most significant variables in explaining wrist fistula maturity failure (positive predictive value 60.6%, 95% confidence interval 43.9% to 77.3%), whereas resistance index and flow rate were most significant for elbow arteriovenous fistulas (positive predictive value 66.7%, 95% confidence interval 48.9% to 84.4%). In contrast to non-maturation, both models predicted fistula maturation much more reliably [negative predictive values of 95.4% (95% confidence interval 91.0% to 99.8%) and 95.6% (95% confidence interval 91.8% to 99.4%) for wrist and elbow, respectively]. Additional follow-up and modelling on a subset (
Conclusions UNASSIGNED
Although early ultrasound can predict fistula maturation and longer-term patency very effectively, it was only moderately good at identifying those fistulas likely to remain immature or to fail within 6 months. Allied to the better- than-expected fistula patency rates achieved (that are further improved by successful salvage), we estimate that a randomised controlled trial comparing early ultrasound-guided intervention against standard care would require at least 1300 fistulas and would achieve only minimal patient benefit.
Trial Registration UNASSIGNED
This trial is registered as ISRCTN36033877 and ISRCTN17399438.
Funding UNASSIGNED
This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: NIHR135572) and is published in full in
For people with advanced kidney disease, haemodialysis is best provided by an ‘arteriovenous fistula’, which is created surgically by joining a vein onto an artery at the wrist or elbow. However, these take about 2 months to develop fully (‘mature’), and as many as 3 out of 10 fail to do so. We asked whether we could use early ultrasound scanning of the fistula to identify those that are unlikely to mature. This would allow us to decide whether it would be practical to run a large, randomised trial to find out if using early ultrasound allows us to ‘rescue’ fistulas that would otherwise fail. We invited adults to undergo serial ultrasound scanning of their fistula in the first few weeks after it was created. We then analysed whether we could use the data from the early scans to identify those fistulas that were not going to mature by week 10. Of the 333 fistulas that were created, about two-thirds reached maturity by week 10. We found that an ultrasound scan 4 weeks after fistula creation could reliably identify those fistulas that were going to mature. However, of those fistulas predicted to fail, about one-third did eventually mature without further intervention, and even without knowing what the early scans showed, another third were successfully rescued by surgery or X-ray-guided treatment at a later stage. Performing an early ultrasound scan on a fistula can provide reassurance that it will mature and deliver trouble-free dialysis. However, because scans are poor at identifying fistulas that are unlikely to mature, we would not recommend their use to justify early surgery or X-ray-guided treatment in the expectation that this will improve outcomes.

Autres résumés

Type: plain-language-summary (eng)
For people with advanced kidney disease, haemodialysis is best provided by an ‘arteriovenous fistula’, which is created surgically by joining a vein onto an artery at the wrist or elbow. However, these take about 2 months to develop fully (‘mature’), and as many as 3 out of 10 fail to do so. We asked whether we could use early ultrasound scanning of the fistula to identify those that are unlikely to mature. This would allow us to decide whether it would be practical to run a large, randomised trial to find out if using early ultrasound allows us to ‘rescue’ fistulas that would otherwise fail. We invited adults to undergo serial ultrasound scanning of their fistula in the first few weeks after it was created. We then analysed whether we could use the data from the early scans to identify those fistulas that were not going to mature by week 10. Of the 333 fistulas that were created, about two-thirds reached maturity by week 10. We found that an ultrasound scan 4 weeks after fistula creation could reliably identify those fistulas that were going to mature. However, of those fistulas predicted to fail, about one-third did eventually mature without further intervention, and even without knowing what the early scans showed, another third were successfully rescued by surgery or X-ray-guided treatment at a later stage. Performing an early ultrasound scan on a fistula can provide reassurance that it will mature and deliver trouble-free dialysis. However, because scans are poor at identifying fistulas that are unlikely to mature, we would not recommend their use to justify early surgery or X-ray-guided treatment in the expectation that this will improve outcomes.

Identifiants

pubmed: 38768043
doi: 10.3310/YTBT4172
doi:

Types de publication

Journal Article Observational Study Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-54

Références

UK Renal Registry. UK Renal Registry 24th Annual Report – Data to 31/12/2020. Bristol. 2022. URL: https://ukkidney.org/audit-research/annual-report (accessed 14 February 2023).
Taylor G, Gravel D, Johnston L, Embil J, Holton D, Paton S; Canadian Nosocomial Infection Surveillance Program. Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. Am J Infect Control 2004;32(3):155–60.
D’Agata EM, Mount DB, Thayer V, Schaffner W. Hospital-acquired infections among chronic hemodialysis patients. Am J Kidney Dis 2000;35(6):1083–8.
Marr KA, Kong L, Fowler VG, Gopal A, Sexton DJ, Conlon PJ, Corey GR. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998;54(5):1684–9.
Rodriguez-Aranda A, Alcazar JM, Sanz F, Garcia-Martin F, Otero JR, Aguado JM, Chaves F. Endoluminal colonization as a risk factor for coagulase-negative staphylococcal catheter-related bloodstream infections in haemodialysis patients. Nephrol Dial Transplant 2011;26(3):948–55.
Rosenbaum D, MacRae JM, Djurdjev O, Levin A, Werb R, Kiaii M. Surveillance cultures of tunneled cuffed catheter exit sites in chronic hemodialysis patients are of no benefit. Hemodial Int 2006;10(4):365–70.
McCann M, Moore ZE. Interventions for preventing infectious complications in haemodialysis patients with central venous catheters. Cochrane Database Syst Rev 2010;2010(1):CD006894.
Engemann JJ, Friedman JY, Reed SD, Griffiths RI, Szczech LA, Kaye KS, et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving long-term hemodialysis. Infect Control Hosp Epidemiol 2005;26(6):534–9.
Astor BC, Eustace JA, Powe NR, Klag MJ, Fink NE, Coresh J; CHOICE Study. Type of vascular access and survival among incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study. J Am Soc Nephrol 2005;16(5):1449–55.
The UK Kidney Association. Vascular Access Guidelines. 2015. URL: https://ukkidney.org/sites/renal.org/files/vascular-access.pdf (accessed 14 February 2023).
Caskey F, Cullen R. UK Renal Registry 18th annual report: introduction. Nephron 2016;132(Suppl 1):1–8.
Schinstock CA, Albright RC, Williams AW, Dillon JJ, Bergstralh EJ, Jenson BM, et al. Outcomes of arteriovenous fistula creation after the fistula first initiative. Clin J Am Soc Nephrol 2011;6(8):1996–2002.
Wells AC, Fernando B, Butler A, Huguet E, Bradley JA, Pettigrew GJ. Selective use of ultrasonographic vascular mapping in the assessment of patients before haemodialysis access surgery. Br J Surg 2005;92(11):1439–43.
Huijbregts HJ, Bots ML, Wittens CH, Schrama YC, Moll FL, Blankestijn PJ; CIMINO Study Group. Hemodialysis arteriovenous fistula patency revisited: results of a prospective, multicenter initiative. Clin J Am Soc Nephrol 2008;3(3):714–9.
Han A, Min SK, Kim MS, Joo KW, Kim J, Ha J, et al. A prospective, randomized trial of routine duplex ultrasound surveillance on arteriovenous fistula maturation. Clin J Am Soc Nephrol 2016;11(10):1817–24.
Voorzaat BM, Janmaat CJ, van der Bogt KEA, Dekker FW, Rotmans JI. Patency outcomes of arteriovenous fistulas and grafts for hemodialysis access: a trade-off between nonmaturation and long-term complications. Kidney360 2020;1(9):916–24.
Al-Jaishi AA, Oliver MJ, Thomas SM, Lok CE, Zhang JC, Garg AX, et al. Patency rates of the arteriovenous fistula for hemodialysis: a systematic review and meta-analysis. Am J Kidney Dis 2014;63(3):464–78.
Badero OJ, Salifu MO, Wasse H, Work J. Frequency of swing-segment stenosis in referred dialysis patients with angiographically documented lesions. Am J Kidney Dis 2008;51(1):93–8.
Ives CL, Akoh JA, George J, Vaughan-Huxley E, Lawson H. Pre-operative vessel mapping and early post-operative surveillance duplex scanning of arteriovenous fistulae. J Vasc Access 2009;10(1):37–42.
Hindle P, Ritchie J, Griffiths G, Howd A. Use of early scanning in fistula formation for vascular access. J Vasc Access 2011;12(2):127–9.
Beathard GA, Lok CE, Glickman MH, Al-Jaishi AA, Bednarski D, Cull DL, et al. Definitions and end points for interventional studies for arteriovenous dialysis access. Clin J Am Soc Nephrol 2018;13(3):501–12.
Saucy F, Haesler E, Haller C, Deglise S, Teta D, Corpataux JM. Is intra-operative blood flow predictive for early failure of radiocephalic arteriovenous fistula? Nephrol Dial Transplant 2010;25(3):862–7.
Robbin ML, Greene T, Cheung AK, Allon M, Berceli SA, Kaufman JS, et al.; Hemodialysis Fistula Maturation Study Group. Arteriovenous fistula development in the first 6 weeks after creation. Radiology 2016;279(2):620–9.
Robbin ML, Greene T, Allon M, Dember LM, Imrey PB, Cheung AK, et al.; Hemodialysis Fistula Maturation Study Group. Prediction of arteriovenous fistula clinical maturation from postoperative ultrasound measurements: findings from the hemodialysis fistula maturation study. J Am Soc Nephrol 2018;29(11):2735–44.
Itoga NK, Ullery BW, Tran K, Lee GK, Aalami OO, Bech FR, Zhou W. Use of a proactive duplex ultrasound protocol for hemodialysis access. J Vasc Surg 2016;64(4):1042.e–1049.e1.
Moist L, Lok CE. Con: vascular access surveillance in mature fistulas: is it worthwhile? Nephrol Dial Transplant 2019;34(7):1106–11.
Tessitore N, Poli A. Pro: vascular access surveillance in mature fistulas: is it worthwhile? Nephrol Dial Transplant 2019;34(7):1102–6.
Anvari E, Vachharajani TJ. The hemodialysis access surveillance controversy continues. Kidney Int Rep 2020;5(11):1848–50.
Goh MA, Ali JM, Iype S, Pettigrew GJ. Outcomes of primary arteriovenous fistulas in patients older than 70 years. J Vasc Surg 2016;63(5):1333–40.
Mousa AY, Dearing DD, Aburahma AF. Radiocephalic fistula: review and update. Ann Vasc Surg 2013;27(3):370–8.
Kazemzadeh GH, Modaghegh MHS, Ravari H, Daliri M, Hoseini L, Nateghi M. Primary patency rate of native AV fistula: long term follow up. Int J Clin Exp Med 2012;5(2):173–8.
Robbin ML, Chamberlain NE, Lockhart ME, Gallichio MH, Young CJ, Deierhoi MH, Allon M. Hemodialysis arteriovenous fistula maturity: US evaluation. Radiology 2002;225(1):59–64.
Singh P, Robbin ML, Lockhart ME, Allon M. Clinically immature arteriovenous hemodialysis fistulas: effect of US on salvage. Radiology 2008;246(1):299–305.
Sidawy AN, Gray R, Besarab A, Henry M, Ascher E, Silva M Jr, et al. Recommended standards for reports dealing with arteriovenous hemodialysis accesses. J Vasc Surg 2002;35(3):603–10.
Hosmer Jr DW, Lemeshow S, Sturdivant RX. Applied Logistic Regression. 3rd edn: John Wiley & Sons, Inc.; 2013.
UK Renal Registry. UK Renal Registry 23rd Annual Report – Data to 31/12/2019. Bristol. 2021. URL: https://ukkidney.org/sites/renal.org/files/23rd_UKRR_ANNUAL_REPORT.pdf (accessed 14 February 2023)
Feldman HI, Joffe M, Rosas SE, Burns JE, Knauss J, Brayman K. Predictors of successful arteriovenous fistula maturation. Am J Kidney Dis 2003;42(5):1000–12.
Farrington CA, Robbin ML, Lee T, Barker-Finkel J, Allon M. Early predictors of arteriovenous fistula maturation: a novel perspective on an enduring problem. J Am Soc Nephrol 2020;31(7):1617–27.
Mendes RR, Farber MA, Marston WA, Dinwiddie LC, Keagy BA, Burnham SJ. Prediction of wrist arteriovenous fistula maturation with preoperative vein mapping with ultrasonography. J Vasc Surg 2002;36(3):460–3.
Collett D. Modelling Survival Data in Medical Research. 3rd edn. London: Chapman & Hall; 2015.
Kerr M, Bray B, Medcalf J, O’Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant 2012;27(Suppl_3):iii73–80.

Auteurs

James Richards (J)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
University of Cambridge, Cambridge, UK.
Royal Free London NHS Foundation Trust, London, UK.

Dominic Summers (D)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
University of Cambridge, Cambridge, UK.

Anna Sidders (A)

NHS Blood and Transplant Clinical Trials Unit, London, UK.

Elisa Allen (E)

NHS Blood and Transplant Clinical Trials Unit, London, UK.

Mohammed Ayaz Hossain (M)

Royal Free London NHS Foundation Trust, London, UK.

Subhankar Paul (S)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
University of Cambridge, Cambridge, UK.

Matthew Slater (M)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Matthew Bartlett (M)

Royal Free London NHS Foundation Trust, London, UK.

Regin Lagaac (R)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Emma Laing (E)

NHS Blood and Transplant Clinical Trials Unit, London, UK.

Valerie Hopkins (V)

NHS Blood and Transplant Clinical Trials Unit, London, UK.

Chloe Fitzpatrick-Creamer (C)

NHS Blood and Transplant Clinical Trials Unit, London, UK.

Cara Hudson (C)

NHS Blood and Transplant Clinical Trials Unit, London, UK.

Joseph Parsons (J)

NHS Blood and Transplant Clinical Trials Unit, London, UK.

Samuel Turner (S)

North Bristol NHS Trust, Bristol, UK.

Andrew Tambyraja (A)

Royal Infirmary of Edinburgh, NHS Lothian, Edinburgh, UK.

Subash Somalanka (S)

Epsom and St Helier University Hospitals NHS Trust, Epsom, UK.

James Hunter (J)

University Hospital Coventry and Warwickshire NHS Trust, Coventry, UK.

Sam Dutta (S)

Nottingham University Hospitals NHS Trust, Nottingham, UK.

Neil Hoye (N)

South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK.

Sarah Lawman (S)

Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.

Tracey Salter (T)

Epsom and St Helier University Hospitals NHS Trust, Epsom, UK.
Frimley Health NHS Foundation Trust, Frimley, UK.

Mohammed Farid Aslam (MF)

Imperial College Healthcare NHS Trust, London, UK.

Atul Bagul (A)

University Hospitals of Leicester NHS Trust, Leicester, UK.

Rajesh Sivaprakasam (R)

Bart's Health NHS Trust, London, UK.

George E Smith (GE)

Hull University Teaching Hospitals NHS Trust, Hull, UK.

Helen L Thomas (HL)

NHS Blood and Transplant Clinical Trials Unit, London, UK.

Zia Moinuddin (Z)

Manchester University NHS Foundation Trust, Manchester, UK.

Simon R Knight (SR)

Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Nicholas Barnett (N)

Guy's and St Thomas' NHS Foundation Trust, London, UK.

Reza Motallebzadeh (R)

Royal Free London NHS Foundation Trust, London, UK.

Gavin J Pettigrew (GJ)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
University of Cambridge, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH